Abbott Laboratories (ABT)
$
103.96
-0.61 (-0.59%)
Key metrics
Financial statements
Free cash flow per share
4.2330
Market cap
180.6 Billion
Price to sales ratio
4.0753
Debt to equity
0.2890
Current ratio
1.5759
Income quality
1.4663
Average inventory
6.6 Billion
ROE
0.1289
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Abbott Laboratories, along with its subsidiaries, is engaged in the discovery, development, manufacturing, and global sale of health care products, operating across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The EBITDA is $11,553,000,000.00 a key indicator of the company's operational profitability. Within the Established Pharmaceutical Products segment, the company markets generic pharmaceuticals to address conditions such as pancreatic exocrine insufficiency and dyslipidemia, as well as providing critical anti-infectives like clarithromycin and an influenza vaccine. The operating expenses amount to $16,586,000,000.00 encompassing various operational costs incurred, while the company reported selling, general, and administrative expenses of $12,378,000,000.00 indicating its operational overhead costs. Furthermore, the diluted EPS is $3.72 accounting for potential share dilution. The Diagnostic Products segment enhances health care with laboratory systems focused on immunoassay and clinical chemistry, alongside molecular diagnostics for infectious agents. The Nutritional Products segment delivers essential nutritional solutions for both pediatric and adult populations, while the Medical Devices segment offers innovative treatments for cardiovascular diseases and diabetes management. Abbott Laboratories, founded in 1888 and based in North Chicago, Illinois, has established itself as a leader in the health care sector. The stock is reasonably priced at $136.04 appealing to a broad range of investors. With a large market capitalization of $180,649,520,833.00 the company is a dominant player in the health care industry, contributing significantly to the overall market landscape. The stock has a high average trading volume of 10,984,633.00 indicating strong liquidity. It is a key player in the Medical - Devices industry, driving innovation and growth, and belongs to the Healthcare sector, further affirming its stature within the competitive health care market. Abbott Laboratories’ commitment to advancement and quality in health care solutions continues to position it for sustained success and relevance.
Is Abbott Laboratories (ABT) a good investment?
Investing in Abbott Laboratories (ABT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
What is Abbott Laboratories (ABT)'s stock forecast?
Analysts predict Abbott Laboratories stock to fluctuate between $103.68 (low) and $139.06 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Abbott Laboratories's market capitalization?
As of 2026-03-30, Abbott Laboratories's market cap is $180,649,520,833, based on 1,737,682,963 outstanding shares.
How does Abbott Laboratories compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Abbott Laboratories has a Lower Market-Cap, indicating a difference in performance.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays dividends. The current dividend yield is 2.40%, with a payout of $0.63 per share.
How can I buy Abbott Laboratories (ABT) stock?
To buy Abbott Laboratories (ABT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABT. Place an order (Market, Limit, etc.).
What is the best time to invest in Abbott Laboratories?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Abbott Laboratories stock ever split?
Abbott Laboratories's last stock split was 5000:2399 on 2013-01-02.
How did Abbott Laboratories perform in the last earnings report?
Revenue: $44,328,000,000 | EPS: $3.74 | Growth: -51.24%.
Where can I find Abbott Laboratories's investor relations reports?
Visit https://www.abbott.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Abbott Laboratories?
You can explore historical data from here
What is the all-time high and low for Abbott Laboratories stock?
All-time high: $142.60 (2021-12-27) | All-time low: $89.67 (2023-10-12).
What are the key trends affecting Abbott Laboratories stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments Advances Abbott's mission to make healthcare more accessible and give people more control over their health ABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people.
fool.com
Defensive stocks should help your portfolio weather the toughest market times. The revenue growth of these companies doesn't depend on the economic backdrop.
fool.com
Abbott Laboratories' latest financial results were not particularly strong. Some of the company's opportunities could help boost sales growth.
zacks.com
Abbott (ABT) closed at $109.95 in the latest trading session, marking a +1.78% move from the prior day.
defenseworld.net
Alliancebernstein L.P. raised its position in shares of Abbott Laboratories (NYSE: ABT) by 51.0% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,525,906 shares of the healthcare product maker's stock after purchasing an additional 1,865,250 shares during the
businesswire.com
MINNEAPOLIS--(BUSINESS WIRE)--Pivot Bio, one of the world's leading innovative agtech companies, will be taking the stage at the World Agri-Tech Innovation Summit taking place March 16–18, 2026. Chris Abbott, chief executive officer, will participate in a fireside chat titled “Capturing Innovation in a Transformed Agri-Food Landscape” on the Main Stage on March 17 at 4:15 p.m. PT. Abbott will be joined by Scott H. Hutchins, Under Secretary for Research, Education, and Economics & Chief Scie.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Abbott (ABT) reached $112.65 at the closing of the latest trading day, reflecting a +2.82% change compared to its last close.
seekingalpha.com
Abbott Laboratories (ABT) remains a Buy, with the stock undervalued at $109.56 despite recent execution missteps and Nutrition segment weakness. Core Devices and Diagnostics segments continue to deliver high single-digit sales growth and double-digit EPS growth, supporting the investment thesis. Nutrition remains a key risk, but management expects a turnaround in the second half; Exact Sciences acquisition could add a new high-growth vertical.
See all news
